A novel patient-derived cutaneous melanoma cell line reveals key features of metastatic melanoma

We established and characterized a novel patient-derived primary cell line, MelT79, developed from a metastatic lesion of a patient initially diagnosed with stage IB cutaneous melanoma (CM), who later progressed to advanced disease. MelT79 serves as a valuable in vitro model for studying CM heterogeneity, progression, and resistance mechanisms. DNA was extracted from MelT79 cells and from an earlier formalin-fixed paraffin-embedded (FFPE) metastasis. Both samples were analysed by next-generation sequencing (NGS), using a custom multigene panel targeting cancer-related genes.